Monard Amaury, Castoldi Elisabetta, De Simone Ilaria, Wichapong Kanin, van Duijl Tirsa, van den Biggelaar Maartje, Spada Stefano, van Doorn William, Hellenbrand Dave, van der Meijden Paola, Swieringa Frauke, Stork Alexander, Ten Cate Hugo, Beckers Erik, Heubel-Moenen Floor, Henskens Yvonne
Department of Internal Medicine-Hematology, Maastricht University Medical Centre+, Maastricht, Netherlands.
CARIM, School for Cardiovascular Disease, Maastricht University, Maastricht, Netherlands.
Front Cardiovasc Med. 2024 Oct 15;11:1488602. doi: 10.3389/fcvm.2024.1488602. eCollection 2024.
Hypodysfibrinogenemia is a rare congenital fibrinogen disorder (CFD) which may induce thrombotic and bleeding events. Therefore, patient management needs careful evaluation. Routine coagulation tests are inadequate to predict the clinical phenotype.
A 60-year-old woman with both bleeding and thrombotic complications and her two daughters were referred to our center for genotypic and phenotypic analysis of a CFD.
Conventional laboratory results led to the diagnosis of hypodysfibrinogenemia in all three subjects. They all carried the same heterozygous c.1124A>G mutation in resulting in p.Tyr375Cys amino acid substitution, which was confirmed by protein variant analysis from plasma. structure analysis predicted possible conformational and functional changes of the fibrinogen molecule. Thrombin generation indicated a hypercoagulable state confirmed by microfluidics that showed enhanced fibrin formation in both daughters, regardless of the coagulation trigger.
We report on a family with hypodysfibrinogenemia and a novel heterozygous missense mutation, possibly leading to conformational changes or covalent dimerization. Thrombin generation and particularly microfluidic measurements disclosed a hypercoagulable state, which was not detected with routine coagulation tests, justifying a different patient management.
低纤维蛋白原血症是一种罕见的先天性纤维蛋白原紊乱(CFD),可能引发血栓形成和出血事件。因此,对患者的管理需要仔细评估。常规凝血试验不足以预测临床表型。
一名患有出血和血栓形成并发症的60岁女性及其两个女儿被转诊至我们中心,以进行CFD的基因型和表型分析。
常规实验室检查结果确诊所有三名受试者均患有低纤维蛋白原血症。他们均携带相同的杂合子c.1124A>G突变,导致p.Tyr375Cys氨基酸替代,这通过血浆蛋白变体分析得到证实。结构分析预测了纤维蛋白原分子可能的构象和功能变化。凝血酶生成表明存在高凝状态,微流控技术证实两个女儿均存在增强的纤维蛋白形成,无论凝血触发因素如何。
我们报告了一个患有低纤维蛋白原血症的家族以及一种新的杂合子错义突变,该突变可能导致构象变化或共价二聚化。凝血酶生成,尤其是微流控测量揭示了一种高凝状态,这是常规凝血试验未检测到的,这证明了对患者进行不同管理的合理性。